Table 1 Multivariate analysis of cohort A for event-free survival (EFS), relapse- free survival (RFS), and overall survival (OS)

From: Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option

Variable

Hazard ratio

95% CI

p-value

Including PVR

ā€ƒEFS

ā€ƒPVR expression

1.68

1.14–2.47

0.009

ā€ƒKaryotype

3.05

1.99–4.66

<0.001

ā€ƒRFS

ā€ƒPVR expression

2.18

1.40–3.40

0.001

ā€ƒKaryotype

2.35

0.40–3.95

0.001

ā€ƒOS

ā€ƒPVR expression

1.52

1.04–2.23

0.032

ā€ƒKaryotype

2.63

1.63–4.24

<0.001

Excluding PVR

ā€ƒEFS

ā€ƒPVRL2 expression

1.16

0.95–1.42

0.150

ā€ƒKaryotype

2.95

1.92–4.55

<0.001

ā€ƒRFS

ā€ƒPVRL2 expression

1.30

1.05–1.61

0.017

ā€ƒKaryotype

2.19

1.29–3.72

0.004

ā€ƒOS

ā€ƒPVRL2 expression

1.17

0.98–1.40

0.087

ā€ƒKaryotype

2.52

0.95–3.10

<0.001

  1. CI confidence interval